Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Fluorouracil

abstract

  • Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.

publication date

  • July 10, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3699725

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.49.6638

PubMed ID

  • 23733765

Additional Document Info

start page

  • 2600

end page

  • 6

volume

  • 31

number

  • 20